Janssen-Cilag International NV - Articles and news items

Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)

Industry news / 24 August 2016 / Janssen-Cilag International NV

Phase 3 data supporting submission suggests potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for relapsed multiple myeloma patients…

Daratumumab significantly extends PFS in multiple myeloma study

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death…

Daratumumab extends PFS in patients with multiple myeloma

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death…

EC grants conditional approval to daratumumab in multiple myeloma

Industry news / 23 May 2016 / Victoria White, Digital Content Producer

Daratumumab is the first CD38-directed mAb approved in Europe. It binds to CD38, a signalling molecule expressed on the surface of multiple myeloma cells…


Janssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients

Industry news / 3 May 2016 / Mandy Parrett, Editorial Assistant

Janssen-Cilag International NV have reported that their therapy IMBRUVICA® (ibrutinib) has received a ‘Positive Opinion’ from the CHMP recommending that its use be extended for CLL patients.

NHS England to fund HIV treatment Rezolsta (darunavir/cobicistat)

Industry news / 30 March 2016 / Victoria White

Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1…

Abiraterone acetate plus prednisone shows survival benefit in early mCRPC

Industry news / 14 March 2016 / Victoria White

In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone…

Ibrutinib shown to be superior to chlorambucil in trial

Industry news / 7 December 2015 / Victoria White

Data from a Phase 3 trial show ibrutinib was superior to chlorambucil in all efficacy endpoints measured in patients with CLL or SLL…

Janssen submits application to EMA to expand use of ibrutinib

Industry news / 4 November 2015 / Victoria White

Janssen seeks to broaden the existing marketing authorisation for ibrutinib to include previously untreated patients with chronic lymphocytic leukaemia…


Ustekinumab gets UK launch for adolescents with psoriasis

Industry news / 14 September 2015 / Victoria White

A clinical study demonstratement that ustekinumab can improve psoriasis symptoms and lessen its impact on quality of life in young people aged 12 and over…

Janssen submits Extension MAA for paliperidone palmitate once-every-three-months formulation

Industry news / 21 August 2015 / Victoria White

Janssen has submitted an Extension MAA to the EMA for paliperidone palmitate once-every-three-months formulation for the treatment of schizophrenia…

Janssen’s ibrutinib approved by the EC for the treatment of Waldenström’s macroglobulinemia

Industry news / 10 July 2015 / Victoria White

The EC has approved Janssen’s Imbruvica (ibrutinib) capsules as a treatment option for adult patients with Waldenström’s macroglobulinemia (WM)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...